Purvalanol A | NG-60 | CDK Inhibitor | AmBeed-信号通路专用抑制剂

Purvalanol A {[allProObj[0].p_purity_real_show]}

货号：A106338 同义名： NG-60

Purvalanol A 是一种 CDK2 抑制剂，对 cdc2-cyclin B、cdk2-cyclin A、cdk2-cyclin E、cdk4-cyclin D1 和 cdk5-p35 的 IC50 值分别为 4、70、35、850、75 nM。

Purvalanol A 化学结构
CAS号：212844-53-6

Purvalanol A 3D分子结构
CAS号：212844-53-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

CDK 亚型比较

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 HCl	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											SGK,ERK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinE, IC50: 35 nM CDK2/CyclinA, IC50: 70 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(C118L), Kd: 18.6 nM CDK2(A144C), Kd: 9.7 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	99%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinE, IC50: 3 nM CDK2/CyclinA, IC50: 4 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinE, IC50: 8 nM CDK2/CyclinA, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinE, IC50: 363 nM CDK2/CyclinA, IC50: 45 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinE, IC50: 7.5μM CDK2/CyclinA, IC50: 0.68μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinE, IC50: 48 nM CDK2/CyclinA, IC50: 38 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 HCl	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	99%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinE, IC50: 0.7 μM CDK2/CyclinA, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD3, IC50: 9 nM CDK4/CyclinD1, IC50: 11 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 2HCl									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				99%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinE, IC50: 2.54 μM CDK2/CyclinA, IC50: 224 nM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			98%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ Dyrk1B , IC50: 1648 nM CLK4, IC50: 136 nM		99%+
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Purvalanol A 生物活性

靶点

CDK4

CDK4/CyclinD1, IC50:850 nM
CDK2

CDK2/CyclinE, IC50:35 nM

CDK2/CyclinA, IC50:70 nM
Cdc

Cdc2/CyclinB, IC50:4 nM

描述

CDK2 is a serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. CDK2 triggers duplication of centrosomes and DNA, acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression. CDK2 controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Purvalanol A is a CDK2 inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, respectively. Based on kinase assays performed in immunoprecipitates, the IC50s of purvalanol A against 2 yeast CDKs (Cdc28p and Pho85p) were 7 μM and 2 μM, respectively^[3]. According to a MTT cell viability assay, purvalanol A induced cell viability loss by 50% in MCF-7 cells at the concentration of 25 μM when incubated in vitro for 24h^[4].In a spinal cord injury model established in Sprague–Dawley rats, 5 μl of purvalanol A at the concentration of 10 mM in DMSO was immediately injected into the injury site. The results were that purvalanol A restricted compaction of the injury cavity and astrocyte infiltration into the cavity. Purvalanol A treatment also attenuated regenerative responses of anterogradely labeled corticospinal tract axons. Moreover, purvalanol A treatments reduced astrocyte migration and in parallel retarded the extension of spinal axon, observed by the technique of implantation of a polymeric tube into the spinal cord^[5].

作用机制

Purvalanol A is a CDK2 inhibitor that acts by blocking the ATP-binding site^[3].

Purvalanol A 细胞实验

Cell Line Human foreskin fibroblasts (HFFs) HeLa cells Jurkat cells Giardia lamblia Human umbilical vein endothelial cells Tet-BZLF1/Akata cells C. elegans embryos Kasumi-1 MV4-11 CMK Tet-BZLF1/B95-8 cells MV4-11 cells MOLM-13 cells MOLM-14 cells HPV31b-positive keratinocytes	Concentration	Treated Time	Description	References
Human foreskin fibroblasts (HFFs)	20 µM	2 days	To evaluate the antiviral effects of Purvalanol A on VZV replication, results showed that Purvalanol A exhibited antiviral activity in cultured HFFs.	Antiviral Res. 2010 Jun;86(3):276-85.
HeLa cells	25 µM	2 hours	To investigate the effect of Purvalanol A on mitotic exit in HeLa cells in the presence of MG132, results showed that Purvalanol A was unable to drive mitotic exit.	J Cell Biol. 2007 Nov 19;179(4):671-85.
Jurkat cells	20 µM	24 hours	Purvalanol A repressed the levels of DHFR protein and enhanced sensitivity to MTX in Jurkat cells.	Cancer Sci. 2010 Mar;101(3):728-34.
Giardia lamblia	10 µM	24 hours	To study the effect of Purvalanol A on Cdk2 kinase activity. Results showed that addition of purvalanol A significantly decreased the Cdk2-associated kinase activity.	J Biol Chem. 2012 Feb 3;287(6):3733-50.
Human umbilical vein endothelial cells	10 µM	30 minutes to 1 hour	To investigate the effect of Purvalanol A on CA-4-P-induced mitotic arrest, results showed that Purvalanol A accelerated the progression of cells through mitosis.	Am J Pathol. 2004 Oct;165(4):1401-11.
Tet-BZLF1/Akata cells	5 µM	48 hours	Inhibited EBV lytic protein expression, almost completely blocking viral protein production	J Virol. 2004 Jan;78(1):104-15.
C. elegans embryos	100 mM	5 minutes	To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening.	elegans. J Cell Biol.
Kasumi-1	0.1 µM and 0.5 µM	72 hours	To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on Kasumi-1 cells. Results showed that the combination significantly increased cell death compared to single agents.	Int J Mol Sci. 2023 Mar 16;24(6):5717.
MV4-11	0.1 µM and 0.5 µM	72 hours	To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on MV4-11 cells. Results showed that the combination significantly increased cell death compared to single agents.	Int J Mol Sci. 2023 Mar 16;24(6):5717.
CMK	0.1 µM and 0.5 µM	72 hours	To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on CMK cells. Results showed that the combination significantly increased cell death compared to single agents.	Int J Mol Sci. 2023 Mar 16;24(6):5717.
Tet-BZLF1/B95-8 cells	15 µM	72 hours	Inhibited EBV lytic replication, almost completely blocking viral DNA amplification	J Virol. 2004 Jan;78(1):104-15.
MV4-11 cells	1.3 µM	72 hours	Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.	Biomacromolecules. 2024 Oct 14;25(10):6503-6514.
MOLM-13 cells	1.3 µM	72 hours	Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.	Biomacromolecules. 2024 Oct 14;25(10):6503-6514.
MOLM-14 cells	1.3 µM	72 hours	Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.	Biomacromolecules. 2024 Oct 14;25(10):6503-6514.
HPV31b-positive keratinocytes	10 nM	from day 8 to day 12	Inhibition of CDK1 kinase activity resulted in the synthesis of noninfectious HPV31b particles	J Virol. 2010 May;84(9):4630-45.

Cell Line

Concentration

Treated Time

Description

References

Human foreskin fibroblasts (HFFs)

20 µM

2 days

To evaluate the antiviral effects of Purvalanol A on VZV replication, results showed that Purvalanol A exhibited antiviral activity in cultured HFFs.

Antiviral Res. 2010 Jun;86(3):276-85.

HeLa cells

25 µM

2 hours

To investigate the effect of Purvalanol A on mitotic exit in HeLa cells in the presence of MG132, results showed that Purvalanol A was unable to drive mitotic exit.

J Cell Biol. 2007 Nov 19;179(4):671-85.

Jurkat cells

20 µM

24 hours

Purvalanol A repressed the levels of DHFR protein and enhanced sensitivity to MTX in Jurkat cells.

Cancer Sci. 2010 Mar;101(3):728-34.

Giardia lamblia

10 µM

24 hours

To study the effect of Purvalanol A on Cdk2 kinase activity. Results showed that addition of purvalanol A significantly decreased the Cdk2-associated kinase activity.

J Biol Chem. 2012 Feb 3;287(6):3733-50.

Human umbilical vein endothelial cells

10 µM

30 minutes to 1 hour

To investigate the effect of Purvalanol A on CA-4-P-induced mitotic arrest, results showed that Purvalanol A accelerated the progression of cells through mitosis.

Am J Pathol. 2004 Oct;165(4):1401-11.

Tet-BZLF1/Akata cells

5 µM

48 hours

Inhibited EBV lytic protein expression, almost completely blocking viral protein production

J Virol. 2004 Jan;78(1):104-15.

C. elegans embryos

100 mM

5 minutes

To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening.

elegans. J Cell Biol.

Kasumi-1

0.1 µM and 0.5 µM

72 hours

To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on Kasumi-1 cells. Results showed that the combination significantly increased cell death compared to single agents.

Int J Mol Sci. 2023 Mar 16;24(6):5717.

MV4-11

0.1 µM and 0.5 µM

72 hours

To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on MV4-11 cells. Results showed that the combination significantly increased cell death compared to single agents.

Int J Mol Sci. 2023 Mar 16;24(6):5717.

CMK

0.1 µM and 0.5 µM

72 hours

To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on CMK cells. Results showed that the combination significantly increased cell death compared to single agents.

Int J Mol Sci. 2023 Mar 16;24(6):5717.

Tet-BZLF1/B95-8 cells

15 µM

72 hours

Inhibited EBV lytic replication, almost completely blocking viral DNA amplification

J Virol. 2004 Jan;78(1):104-15.

MV4-11 cells

1.3 µM

72 hours

Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.

Biomacromolecules. 2024 Oct 14;25(10):6503-6514.

MOLM-13 cells

1.3 µM

72 hours

Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.

Biomacromolecules. 2024 Oct 14;25(10):6503-6514.

MOLM-14 cells

1.3 µM

72 hours

Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity.

Biomacromolecules. 2024 Oct 14;25(10):6503-6514.

HPV31b-positive keratinocytes

10 nM

from day 8 to day 12

Inhibition of CDK1 kinase activity resulted in the synthesis of noninfectious HPV31b particles

J Virol. 2010 May;84(9):4630-45.

Purvalanol A 动物实验

Species C. elegans SCID-Hu mice	Animal Model Wild-type and APC mutant embryos Skin xenograft model	Administration	Dosage	Frequency	Description	References
C. elegans	Wild-type and APC mutant embryos	Uterine injection	100 mM	Single injection, lasting 5 minutes	To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening.	elegans. J Cell Biol.
SCID-Hu mice	Skin xenograft model	Intraperitoneal injection	20 mg/kg/day and 10 mg/kg/day	Once daily for 7 days	To evaluate the antiviral effects of Purvalanol A in the SCID-Hu mouse model, results showed that Purvalanol A failed to effectively inhibit VZV replication.	Antiviral Res. 2010 Jun;86(3):276-85.

Species

C. elegans SCID-Hu mice

Animal Model

Wild-type and APC mutant embryos Skin xenograft model

Administration

Dosage

Frequency

Description

References

C. elegans

Wild-type and APC mutant embryos

Uterine injection

100 mM

Single injection, lasting 5 minutes

To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening.

elegans. J Cell Biol.

SCID-Hu mice

Skin xenograft model

Intraperitoneal injection

20 mg/kg/day and 10 mg/kg/day

Once daily for 7 days

To evaluate the antiviral effects of Purvalanol A in the SCID-Hu mouse model, results showed that Purvalanol A failed to effectively inhibit VZV replication.

Antiviral Res. 2010 Jun;86(3):276-85.

Purvalanol A 动物研究

Dose

Mice: 30 mg/kg^[3] (i.v.)

Administration

i.v.

Purvalanol A 参考文献

Purvalanol A 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.86mL

2.57mL

1.29mL

25.71mL

5.14mL

2.57mL

Purvalanol A 技术信息

CAS号	212844-53-6
分子式	C₁₉H₂₅ClN₆O
分子量	388.89
SMILES Code	CC(C)[C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO
MDL No.	MFCD02179211

别名	NG-60
运输	蓝冰
InChI Key	PMXCMJLOPOFPBT-HNNXBMFYSA-N
Pubchem ID	456214

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(128.57 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 8 mg/mL(20.57 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

Purvalanol A {[allProObj[0].p_purity_real_show]}

Purvalanol A 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Purvalanol A 质控信息

Purvalanol A 生物活性

Purvalanol A 细胞实验

Purvalanol A 动物实验

Purvalanol A 动物研究

Purvalanol A 参考文献

Purvalanol A 实验方案

Purvalanol A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	CDK4 CDK4/CyclinD1, IC50:850 nM CDK2 CDK2/CyclinE, IC50:35 nM CDK2/CyclinA, IC50:70 nM Cdc Cdc2/CyclinB, IC50:4 nM
描述	CDK2 is a serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. CDK2 triggers duplication of centrosomes and DNA, acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression. CDK2 controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Purvalanol A is a CDK2 inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, respectively. Based on kinase assays performed in immunoprecipitates, the IC50s of purvalanol A against 2 yeast CDKs (Cdc28p and Pho85p) were 7 μM and 2 μM, respectively^[3]. According to a MTT cell viability assay, purvalanol A induced cell viability loss by 50% in MCF-7 cells at the concentration of 25 μM when incubated in vitro for 24h^[4].In a spinal cord injury model established in Sprague–Dawley rats, 5 μl of purvalanol A at the concentration of 10 mM in DMSO was immediately injected into the injury site. The results were that purvalanol A restricted compaction of the injury cavity and astrocyte infiltration into the cavity. Purvalanol A treatment also attenuated regenerative responses of anterogradely labeled corticospinal tract axons. Moreover, purvalanol A treatments reduced astrocyte migration and in parallel retarded the extension of spinal axon, observed by the technique of implantation of a polymeric tube into the spinal cord^[5].
作用机制	Purvalanol A is a CDK2 inhibitor that acts by blocking the ATP-binding site^[3].

CDK4	CDK4/CyclinD1, IC50:850 nM
CDK2	CDK2/CyclinE, IC50:35 nM CDK2/CyclinA, IC50:70 nM
Cdc	Cdc2/CyclinB, IC50:4 nM

Purvalanol A {[allProObj[0].p_purity_real_show]}

Purvalanol A 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Purvalanol A 质控信息

Purvalanol A 生物活性

Purvalanol A 细胞实验

Purvalanol A 动物实验

Purvalanol A 动物研究

Purvalanol A 参考文献

Purvalanol A 实验方案

Purvalanol A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Purvalanol A 纯度/质量文件产品仅供科研